Verve Therapeutics to Participate in the 2022 Jefferies Healthcare Conference
Verve Therapeutics will showcase its innovative approach to treating cardiovascular disease at the 2022 Jefferies Healthcare Conference. Co-founder and CEO Sekar Kathiresan will speak on June 8, 2022, at 1:00 p.m. ET in NYC. The company focuses on single-course gene editing medicines, specifically targeting PCSK9 and ANGPTL3 genes to lower LDL cholesterol levels. Verve’s lead candidate, VERVE-101, aims to reduce cardiovascular risk by permanently turning off the PCSK9 gene in the liver. A live webcast will be available on their investor website and archived for 60 days.
- None.
- None.
CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in a fireside chat during the 2022 Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 1:00 p.m. ET in NYC.
A live webcast will be available in the investor section of the company's website at www.vervetx.com. The webcast will be archived for 60 days following the presentation.
About Verve Therapeutics
Verve Therapeutics, Inc. (Nasdaq: VERV) is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company’s initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease. Verve’s lead product candidate, VERVE-101, is designed to permanently turn off the PCSK9 gene in the liver in order to disrupt blood PCSK9 protein production and thereby durably reduce blood LDL-C levels, with the goal of reducing a patient’s risk for cardiovascular disease. VERVE-101 is being developed initially for the treatment of patients with heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease. For more information, please visit www.VerveTx.com.
Investor Contact
Jen Robinson
Verve Therapeutics, Inc.
jrobinson@vervetx.com
Media Contact
Gina Nugent
Ten Bridge Communications
gina@tenbridgecommunications.com
FAQ
What is the focus of Verve Therapeutics as mentioned in the press release?
When will Sekar Kathiresan participate in the 2022 Jefferies Healthcare Conference?
What is the goal of Verve Therapeutics' lead product candidate, VERVE-101?
Where can I watch the live webcast of the fireside chat?
How long will the webcast of the conference be available after the event?
